Hospital Acquired Disease Testing
Hospital Acquired Disease Testing Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023
Press Release :
Global Hospital Acquired Disease Testing Market Insights
The rising incidence of hospital acquired infections (HAIs) has emerged as a major concern for governments, particularly across developing and underdeveloped countries. In first world countries such as the U.S., various regulations are in place for penalizing hospitals exhibiting a high incidence of HAIs. Such regulations augur well for the hospital acquired disease testing market in developed countries. In contrast, the absence of proper regulations and stringent policies limiting the adoption of molecular-biology-based diagnostics are restricting the expansion of the market across emerging nations.
Nevertheless, Transparency Market Research (TMR) forecasts the market to gain considerable momentum in the forthcoming years with the advent of the latest technologies. As per TMR, the global hospital acquired disease testing market stood at US$416.7 mn in 2014. Exhibiting a CAGR of 19.9% CAGR between 2015 and 2023, the market is expected to reach US$2.07 bn by the end of 2023.
Demand from Asia Pacific to Surge as the Region Witness High Incidence of HAIs
Regionally, Europe, Asia Pacific, North America, and Rest of the World constitute the key markets for hospital acquired disease testing. Among these regions, North America held a dominant share of 38.5% in the market in 2014. Europe, in the same year, emerged as the second-largest market with a share of 21.6%. With over a million people suffering from hospital acquired infection, leading to several deaths every year, the U.S. emerged as the largest market for hospital acquired disease testing in North America.
Other than the rising demand from the diagnostic market, the latest advancements in molecular diagnostics have been propelling the market in the region. Favorable regulations implemented to prevent the prevalence of HAIs also support the market’s growth in North America.
TMR forecasts Asia Pacific to exhibit the fastest growth for hospital acquired disease testing. The incidence of nosocomial infections is considerably high in the region. Moreover, Asia Pacific also has stringent regulations in place aimed at curbing HAIs. This, combined with the rising investment in the healthcare infrastructure, is a primary contributor to the hospital acquired disease testing market in the region. The Asia Pacific market is expected to surge at the highest CAGR of 21.2% between 2015 and 2023.
Increasing Incidence of Urinary Tract Infections Fuels Demand for Hospital Acquired Disease Testing
Urinary tract infection is one of the most common hospital acquired infections affecting millions around the world. It has therefore emerged as the largest segment in the global hospital acquired disease testing market, based on test type. As per TMR, the segment was valued at US$155.3 mn in 2014. Rising at a CAGR of 19.8%, the urinary tract infection testing segment is forecast to reach 768.8 mn in 2023.
Apart from this, the demand for hospital acquired disease testing will also rise in response to the increasing incidence of surgical site infection, pneumonia, and MRSA, which is considered the fastest growing HAI in the world. Hospital acquired disease testing is also used for the bloodstream test.
Some of the leading players operating in the global hospital acquired disease testing market are L Hoffman La Roche, Gen-Probe Inc., Diatherix Laboratories Inc., Life Technologies Corporation, Qiagen GmbH, Cantel Medical Corporation, Nordion, Inc., Cepheid, Inc., Meridian Biosciences, and others.
This report covers the market analysis for various diagnostic tests performed to detect hospital associated infections, also called as nosocomial infections. Morbidity rate of nosocomial infections is increasing rapidly worldwide, thereby driving the hospital associated infection (HAI) diagnostic market towards remarkable growth. The stakeholders for this study include manufacturers and providers of diagnostic solutions for nosocomial infections.
The global hospital acquired disease testing market is categorized on the basis of test types, i.e., urinary tract infection, surgical site infection, pneumonia, blood stream infection, MRSA infection, and others. A detailed market analysis and forecast for these segments has been provided in this study, in terms of market revenue (US$ Mn) for the period 2013 to 2023. The report also provides with the compounded annual growth rate (CAGR %) for each infection type for the forecast period 2015 to 2023, while market size estimations have been made considering 2014 as the base year.
In terms of geographical distribution, the global hospital acquired disease testing market has been classified into four geographical areas: North America, Europe, Asia Pacific, Latin America and the Middle East & Africa. The current and future market sizes (in terms of US$ Mn) of the above regional markets have been provided in the report for the period 2013 to 2023 with their growth rate (%) for the period 2015 to 2023. The study further offers recommendations and highlights of the market, which would be useful for the current and future market players to sustain and grow in the global hospital acquired disease testing market.
The market overview section of the report demonstrates the market dynamics and market trends such as the drivers, restraints and opportunities that influence the current nature and future status of this field. Impact factors such as market attractiveness analysis and Porter’s five forces analysis have also been explained in the market overview section of the report, in order to give a thorough analysis of the overall competitive scenario in the global hospital acquired disease testing market.
This report concludes with the company profiles section which includes key information about the major players in this market. Some of the key players profiled in this report include Diatherix Laboratories Inc., Gen-Probe Inc., Qiagen GmbH, L Hoffman La Roche, Cepheid, Inc., Life Technologies Corporation, Meridian Biosciences, Cantel Medical Corporation, Nordion, Inc. and others.
The global hospital acquired disease testing market is segmented as follows:
Global Hospital Acquired Disease Testing Market, by Test
- Pneumonia infection
- Urinary tract infection
- Blood stream associated infection
- Surgical site infection
- MRSA infection
Global Hospital Acquired Disease Testing Market, by Geography
- North America
- Rest of Europe
- Asia Pacific
- Rest pf APAC
- Latin America
- Rest of LATAM
- Middle East & Africa
- Saudi Arabia
- Rest of MEA